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The HLA-DR15 haplotype confers the largest part of the genetic risk to develop multiple sclerosis, a prototypic CD4 + T cell-
mediated autoimmune disease. The mechanisms how certain HLA-class II molecules functionally contribute to autoimmune
diseases are still poorly understood, but probably involve shaping an autoimmune-prone T cell repertoire during central toler-
ance in the thymus and subsequently maintaining or even expanding it in the peripheral immune system. Self-peptides that are
presented by disease-associated HLA-class II molecules most likely play important roles during both processes. Here, we
examined the functional involvement of the HLA-DR15 haplotype in autologous proliferation in multiple sclerosis and the
contribution of HLA-DR15 haplotype-derived self-peptides in an in vitro system. We observe increased autologous T cell
proliferation in patients with multiple sclerosis in relation to the multiple sclerosis risk-associated HLA-DR15 haplotype.
Assuming that the spectrum of self-peptides that is presented by the two HLA-DR15 allelic products is important for sustaining
autologous proliferation we performed peptide elution and identification experiments from the multiple sclerosis-associated
DR15 molecules and a systematic analysis of a DR15 haplotype-derived self-peptide library. We identify HLA-derived self-
peptides as potential mediators of altered autologous proliferation. Our data provide novel insights about perturbed T cell
repertoire dynamics and the functional involvement of the major genetic risk factor, the HLA-DR15 haplotype, in multiple
sclerosis.
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Introduction
Multiple sclerosis is considered a CD4 + T cell-mediated autoim-
mune disorder of the CNS characterized by inflammation, demye-
lination, glial scarring and axonal/neuronal loss (Sospedra and
Martin, 2005). Regarding disease aetiology, genome-wide associ-
ation studies have identified a large number of genetic loci, which,
together with multiple environmental factors, confer multiple scler-
osis risk (Sawcer et al., 2011). The association between human
leucocyte antigen (HLA)-DR15 (formerly called DR2) and multiple
sclerosis was first noticed in 1973 (Jersild et al., 1973), and since
then has been among the most reproduced findings in major
histocompatibility complex (MHC) genetics (Oksenberg et al.,
2008). Furthermore, HLA-DR15 also influences clinical aspects
like disease onset and phenotype (Hensiek et al., 2002).
However, the mechanisms of how the presence of a specific
HLA-DR type, other multiple sclerosis risk alleles and environmen-
tal factors translate to disease are largely unknown. Data from
animal models and immunological studies in patients with multiple
sclerosis point at a role for autoreactive CD4 + T cells in multiple
sclerosis (Sospedra and Martin, 2005). The most important, albeit
indirect finding, supporting this notion is the fact that 10–60%
of the genetic risk stems from the HLA-DR15 haplotype consisting
of two DR alleles, DRB1*15:01 (the heterodimer of DRA1*01:01/
DRB1*15:01, also referred to as DR2b) and DRB5*01:01 (the
heterodimer of DRA1*01:01/DRB5*01:01, also referred to as
DR2a) (Oksenberg et al., 2008). Interestingly, the influence of
the environmental risk factors that have been identified for mul-
tiple sclerosis thus far, i.e. infection with Epstein-Barr virus, low
vitamin D levels, and smoking, is enhanced in DR15 + patients
with multiple sclerosis (Kakalacheva et al., 2011).
HLA-class II molecules are expressed by antigen-presenting cells.
They present peptides derived from processing of self or exogen-
ous proteins, and the complexes of self HLA-class II and antigenic
peptides serve as recognition structures for CD4 + T cells. In the
thymus HLA-class II molecules are involved in shaping the CD4 +
T cell receptor repertoire through central tolerance mechanisms of
positive and negative selection of T cells (Ashton-Rickardt et al.,
1994). Once in the peripheral immune system the T cell repertoire
is maintained by homeostatic proliferation, and interactions be-
tween CD4 + T cells and their T cell receptors with HLA-class
II/self-peptide complexes as well as the cytokines interleukin 7
(IL-7) and IL-15 are the most important stimuli during this process
(Sprent and Surh, 2011). Despite the well-known role of HLA-class
II in T cell receptor repertoire generation and maintenance, our
understanding about the functional contribution of HLA-class II
molecules to human autoimmune diseases in general and also to
multiple sclerosis is, however, still limited.
Regarding possible mechanisms several hypotheses have been
developed including preferential presentation of self-peptides with
similarities to foreign antigens but also tissue-specific autoantigens
(Wucherpfennig and Strominger, 1995), less complete thymic de-
letion of autoreactive T cells (Klein et al., 2000), and differential
HLA-class II expression in certain immune cells and the brain (Prat
et al., 2005). Another interesting possibility, which has not been
examined thus far in multiple sclerosis, is that distinct structural
features of the HLA-DR15 haplotype, i.e. of HLA-DR molecules
themselves or the complexes between HLA molecule and self-pep-
tide, operate through homeostatic proliferation and/or autologous
expansion to shape an autoimmunity-prone T cell repertoire
(Haegert, 2011). Homeostatic T cell proliferation depends on
interactions between T cell receptor and self-peptides presented
by HLA molecules and the cytokines IL-7 and IL-15 (Sprent and
Surh, 2011). Interestingly, genes coding for components of these
and related molecules, i.e. DR15, IL7RA, IL7 and IL2RA, are asso-
ciated with multiple sclerosis risk (Sawcer et al., 2011).
Evidence for alterations in CD4 + T cell selection and/or periph-
eral T cell repertoire maintenance in multiple sclerosis are: myelin-
reactive T cells with a proinflammatory phenotype, lack of CD28
expression, and higher antigen avidity are increased in patients
with multiple sclerosis (Martin et al., 1990; Ota et al., 1990;
Pette et al., 1990; Markovic-Plese et al., 2001; Bielekova et al.,
2004). Further, reduced thymic output of CD4 + T cells has been
observed in multiple sclerosis (Hug et al., 2003; Duszczyszyn
et al., 2006; Haegert et al., 2011) as well as reduced numbers
and function of CD4 + T regulatory cells (Viglietta et al., 2004).
Studies of the T cell repertoire by complementary region determin-
ing region 3 spectratyping indicate reduced diversity in patients
with multiple sclerosis compared with age-matched controls
(Laplaud et al., 2004). These observations indicate alterations of
the peripheral proliferation and survival/expansion of CD4 + T
cells, which might affect antigen avidity and frequency of auto-
reactive T cells. Hence, alterations in T cell homeostasis could con-
tribute to T cell repertoire perturbations in multiple sclerosis.
Given the prominent role of HLA-DR15 for multiple sclerosis
risk, we wanted to investigate its functional involvement in au-
tologous T cell expansion in multiple sclerosis. To this end, we
devised an in vitro method to assess autologous proliferation.
Different from the previously well examined autologous mixed
lymphocyte reaction of human peripheral blood mononuclear
cells (PBMCs), which is reduced in multiple sclerosis and other
autoimmune diseases (Hafler et al., 1985), we did not expose
autologous responder (T lymphocytes) cells to autologous,
gamma-irradiated non-T cells as stimulators, but rather seeded
unmanipulated PBMCs in a serum-free media. Hereby we
addressed first, if autologous T cell proliferation is altered in pa-
tients with multiple sclerosis in general and if there is a relation to
the DR15 haplotype. Next, we dissected the relative role of self-
peptides bound to DR2a and DR2b by two approaches: (i) elution
and identification of self-peptides bound to DR2a or DR2b; and
(ii) based on the fact that HLA-derived-peptides themselves are
frequently presented by HLA-class II alleles, we used overlapping
peptides spanning the sequences of the two DR- and the DQ
molecules of the DR15 haplotype, i.e. the non-polymorphic DR
chain DRA1*01:01, the two DRb chains DRB1*15:01 and
DRB5*01:01, and the tightly linked DQw6 molecule consisting
of DQA1*01:02 and DQB1*06:02, as antigens. Our data demon-
strate that autologous proliferation is increased in patients with
multiple sclerosis, which is related to the presence and dose of
HLA-DR15 expression, that this phenomenon is observed with
both DR alleles expressed in the DR15 haplotype and that HLA-
class II-derived self-peptides are likely involved as antigens.
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Materials and methods
Patients and healthy donors
Patients with multiple sclerosis had clinically definite multiple sclerosis
by clinical and/or McDonald criteria. We examined 69 untreated pa-
tients with multiple sclerosis, eight patients with clinically isolated syn-
drome, a pre-stage of relapsing-remitting multiple sclerosis that often
evolves into multiple sclerosis, based on MRI- and clinical findings; 37
patients with relapsing-remitting multiple sclerosis (eight of these
in exacerbation), eight patients with secondary-progressive multiple
sclerosis , i.e. the multiple sclerosis form that evolves from relapsing-
remitting multiple sclerosis; and finally eight patients with primary-pro-
gressive multiple sclerosis. Signed informed consent was obtained from
all patients and donors under a protocol that was approved by the
Ethics Committee of the Hamburg Board of Physicians (No. 2758).
Samples were typed for HLA class II (DRB1*, DRB3*, DRB4*,
DRB5*, DQA1* and DQB1*) at the Department of Transfusion
Medicine, UKE Hamburg by a reverse sequence-specific oligos in-
house test. In some cases the results were verified by a commercial
reverse sequence-specific oligos test (Dynal RELI-SSO, Invitrogen) or
by Atria SBT (Sequence Based Typing, Abbott). HLA-DR15 + indicates
the haplotype HLA-DRB1*15:01, HLA-DRB5*01:01, HLA-
DQA1*01:02 and HLA-DQB1*06:02. *X indicates another HLA class
II haplotype, and *protective indicates HLA-DRB1*14 or HLA-DRB*11
haplotypes (Ramagopalan et al., 2007). PBMCs were freshly isolated
from EDTA-containing blood tubes or from buffy coats by Ficoll
density gradient centrifugation (PAA). All isolated PBMCs were cryo-
preserved in media containing 10% dimethyl sulfoxide (DMSO;
AppliChem) and stored at 180C.
Proliferative assays
After thawing 2  105 PBMCs/well (average of 22 wells per donor)
were cultured with serum-free AIM-V medium (GIBCO, Invitrogen),
containing 2 mM L-glutamine, 50mg/ml streptomycin sulphate,
10 mg/ml gentamicin sulphate and human albumin, in 96-well U-
bottom microtitre plates (Greiner Bio-One) at 37C, 5% CO2.
Depending on the experiment, wells were pulsed at Day 0, 2 and 6
cells for 15 h with 1 mCi of methyl-3H-thymidine (Hartmann Analytic)
and incorporation was measured by b-scintillation counting (Wallac
1450, Perkin Elmer) (Supplementary Fig. 1A). Phytohaemagglutinin-L
(1 mg/ml, Sigma) was used as positive control.
HLA-DR15 haplotype-derived self-peptides were either tested in
pools or individually at a 2 mM concentration (10 mM total pool con-
centration) in 7-day proliferation assays. Stimulatory indices were cal-
culated as follows: stimulatory indices = mean counts per minute
(peptide) / mean counts per minute (unstimulated). Statistical analysis
was performed using a student’s t-test (two-tailed, unpaired) using
Prism 5.0 software (GraphPad). Analysis of the mean standard deva-
tions has been verified with tests for the homogeneity of variance
(Fligner-Killeen, Bartlett, Levene), which have been performed using
R (v 2.15.1) with libraries stats and car.
Human leucocyte antigen restriction
CD4 + T cells were negatively enriched from thawed PBMCs of HLA-
DR15 + healthy donors using the IMag system (BD Biosciences).
25.000 CD4 + T cells (purity4 95%) were co-cultured for 3 days
with 6.5  104 irradiated (200 Gy) bare lymphocyte syndrome cells
in AIM-V serum-free medium. Restriction was tested with bare
lymphocyte syndrome cells transfected with a single HLA-class II mol-
ecule, DRB1*15:01 (DR2b: DRB1*15:01, DRA*01:01), DRB5*01:01
(DR2a: DRB5*01:01, DRA*01:01), DQw6 (DQA1*01:02,
DQB1*06:02). Bare lymphocyte syndrome cells were kindly provided
by G. Nepom and W. Kwok (University of Washington, Seattle, USA).
Proliferation was assessed as described above.
Blocking of autologous proliferation
Autologous T cell proliferation was blocked by incubating PBMCs with
anti-HLA-class I (HLA-A, -B, -C; w6/32) and anti-HLA-DR (L243)
antibodies at the depicted concentrations and compared with a pur-
ified mouse IgG2a low endotoxin, azide-free isotype control
(BioLegend, MOPC-173) in a 3- and 7-day proliferation assay.
Flow cytometry analysis
Samples were thawed, Fc-blocked with mouse IgG and directly stained
for surface expression using following antibodies: anti-CD3 (PE-Cy7,
UCHT1, eBioscience), anti-CD4 (APC, RPA-T4, eBioscience), anti-CD8
(PacificBlue, DK25, Dako), anti-CD14 (PacificBlue, M’P9, BD
Pharmingen), anti-CD19 (PacificBlue, HIB19, BD Pharmingen), anti-
CD303 (APC, AC144, Miltenyi Biotech), anti-panHLA-class II (DR,
DQ, DP) (FITC, Tu¨39, BD Pharmingen). Analyses were performed on
a LSRII (BD Biosciences) flow cytometer using FACS Diva 5.0 software.
Elution of human leucocyte-presented
peptides
HLA-bound peptides were obtained by immunoprecipitation of HLA
molecules from the bare lymphocyte syndrome cells expressing only
DR2a or DR2b according to standard protocols (Falk et al., 1991)
using the DRB5*01:01-specific antibody (clone: H0596) for DR2a
and the DRB1*15:01-specific antibody (clone: H0427A) for the
DR2b cells. Both were provided by Jar-How Lee (One Lambda
Incorporation). This was followed by a second HLA-precipitation by
the pan-HLA-DR specific antibody L243 for each cell lysate.
About 3 ml cell pellet per cell line were gently shaken in 3 ml PBS
containing 1.2% (w/v) CHAPS in the presence of protease inhibitors
(Complete Protease Inhibitor Cocktail Tablets, Roche Applied Science)
for 1 h followed by sonication of the lysate on ice with subsequent
shaking for 1 h. The lysate was centrifuged and the supernatant was
passed through a 0.20 mm sterile filter. Subsequently, HLA molecules
and bound peptides were isolated with the solid-phase bound mono-
clonal antibody by immunoaffinity chromatography (overnight at 4C).
HLA ligands were eluted with 0.2% trifluoroacetic acid, ultrafiltrated
through a 10-kDa cut-off Amicon ultracentrifuge filter and lyophilized.
Liquid chromatography-mass
spectrometry
Lyophilized samples were resuspended in 30 ml of solvent A [0.1 (v/v)
formic acid in 2% (v/v) acetonitrile] and loaded onto a C18 precolumn
(Dionex) for concentration and desalting with a flow rate of 20 ml/min.
The precolumn was placed in line for separation by a 250  0.075 mm
fused silica microcapillary column packed with C18 reversed-phase ma-
terial (Acclaim PepMap 100, Dionex). A binary gradient of 0 to 55%
solvent B was performed within 120 min, applying a flow rate of 300
nl/min.
The eluted peptides were analysed by electrospray ionization (ESI)
mass spectrometry on a linear trap quadrupole (LTQ) Orbitrap XL
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mass spectrometer (Thermo Fisher Scientific) coupled to nanoLC-2D
(Eksigent) nano-HPLC system through a nanospray-ESI source. A gold-
coated fused-silica glass capillary PicotipTM Emitter (SilicaTipTM, FS360-
20-10 Coating P200P, New Objective) was used for the introduction
into the nanospray-ESI source. The heated capillary temperature and
spray voltage were held at 200C and 1.9 kV, respectively, creating an
electrospray between the Picotip and the transfer capillary resulting in
a sample flow rate of 300 nl/min. Parent ions were measured in the
Fourier transform Orbitrap analyser. Fragment ions were generated by
collision-induced dissociation with normalized collision energy of 35 V
and recorded in the LTQ. The activation time for collision-induced
dissociation was 30 ms. Mass spectrometry-survey scans were acquired
at a resolution of 60 000 at 400 m/z. The ‘lock mass’ option (Olsen
et al., 2005) was enabled for the Fourier transform-mass spectrometry
scans using the 445.120025 m/z ion for real time internal calibrations.
The five most abundant parent ions from the Fourier transform survey
scan were selected for fragmentation and excluded from further
sequencing for 90 s. The mass spectrometer was operated in positive
ion mode and parent ions with an unknown or higher charge state
than three were excluded from tandem mass spectrometry.
Mass spectrometrical data analysis
Tandem mass spectrometry data were analysed with the Thermo
Proteome Discoverer 1.1 (Thermo Fisher Scientific) software employing
Mascot v2.2 (Matrix Science) as a search engine for peptide identifi-
cation using a target-decoy database search in the Swiss-Prot protein
sequence database (Homo sapiens, release, 2010_10). For database
searches a mass tolerance of 5 ppm were used for Fourier transform-
mass spectrometry scans whereas 0.5 Da were accepted for LTQ-MS/
MS scans. The false discovery rate was set to 41%. Phosphorylation
of serine (S), threonine (T) and tyrosine (Y) as well as oxidation of
methionine to methionine sulphoxide (m) were enabled as dynamic
modifications. The software was allowed to group spectra if the
retention time difference did not exceed 24 s.
Peptide library generation and in silico
peptide binding prediction
One hundred and twenty-two overlapping (five amino acid overlap)
15-mer and a few 16-mer peptides from DRB1*15:01, DRB5*01:01,
DRA*01:01, DQA1*01:02, DQB1*06:02 (http://hla.alleles.org) were
synthesized and provided by peptides & elephants GmbH. DRb-chain-
derived peptides with identical sequences were only synthesized once.
Lyophilized peptides were resuspended in 100% dimethyl sulphoxide
and stored at 80C.
In silico peptide binding predictions were performed by the consen-
sus approach provided by the Immune Epitope Database (www.iedb.
org, Wang et al., 2008). Gene Ontology annotation analysis of biolo-
gical pathways was performed with the DAVID functional annotation
analysis webpage (http://david.abcc.ncifcrf.gov/).
Results
Autologous proliferation is altered in
patients with multiple sclerosis
We first characterized and compared in a standard thymidine
incorporation assay the proliferation of PBMCs from 69 untreated
patients with multiple sclerosis and 36 healthy donors (for demo-
graphics see Supplementary Table 1) over 7 days in serum-free
media. Below, we will refer to this condition in the absence of a
stimulus as autologous proliferation. Because there is no back-
ground control and a stimulation index cannot be calculated, we
expressed the strength of proliferation by the mean counts per
minute of all wells (Fig. 1A) and the variation or heterogeneity
by the mean, amongst multiple donors within each group, e.g.
multiple sclerosis or controls, of the standard deviation of all
wells within each donor (Fig. 1B; schematic depiction in
Fig. 1C). PBMCs from patients with multiple sclerosis incorporated
significantly more thymidine (mean counts per minute  SEM,
5337  548) than healthy donors (3606  503, P = 0.04),
whereas no differences in strength of proliferation were observed
after phytohaemagglutinin stimulation (Fig. 1A). PBMCs from
patients with multiple sclerosis not only incorporated more thymi-
dine, but also the variation between wells was significantly higher
or heterogeneous (SD  SEM, 2099  217) than in healthy donors
(1422  180, P = 0.04) (Fig. 1B), and again no differences in het-
erogeneity were observed after phytohaemagglutinin stimulation
(data not shown). Some wells from patients with multiple sclerosis
proliferated as vigorously as usually observed upon stimulation
with nominal antigen (Fig. 1C), suggesting that some T cells
from patients with multiple sclerosis are activated in the absence
of a stimulus. We then compared patients with different forms of
multiple sclerosis, i.e. clinically isolated syndrome, a pre-stage of
multiple sclerosis, relapsing-remitting multiple sclerosis, relapsing-
remitting multiple sclerosis in remission or in exacerbation (relap-
sing-remitting multiple sclerosis-relapse), secondary-progressive
multiple sclerosis and primary-progressive multiple sclerosis.
The differences of the strength of proliferation were similar in
the subgroups, whereas the heterogeneity measure was higher
for patients with clinically isolated syndrome and patients with
relapsing-remitting multiple sclerosis in relapse (Supplementary
Fig. 1B). In order to exclude that a leuco- or lymphopenic
condition of the donors/patients with increased autologous prolif-
eration elicited homeostatic proliferation, i.e. growth of T lympho-
cytes to fill an empty or partially emptied niche, we performed
differential blood counts on all donors. Only two healthy donors
showed lymphocyte counts slightly below normal values, and
there was no correlation between peripheral blood white cell or
lymphocyte counts and the degree of autologous proliferation
(data not shown).
Increased autologous proliferation
is related to the multiple
sclerosis-associated DR15 haplotype
We next addressed the involvement of the HLA-DR15 haplotype
in the above findings. As shown in Fig. 2A, the strength of
autologous proliferation (mean counts per minute) was higher in
DR15 + individuals than in DR15 when comparing all studied
individuals and also in patients with multiple sclerosis versus
healthy donors, although differences were only significant for
DR15 healthy donors versus DR15 + patients with multiple
sclerosis (P = 0.045). The differences were more pronounced for
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the proliferation heterogeneity (mean SD) of all studied DR15 +
versus DR15 individuals (P = 0.004) and for both DR15 versus
DR15 + healthy donors (P = 0.047) and DR15 versus DR15 +
patients with multiple sclerosis (P = 0.036) indicating that autolo-
gous proliferation strength and heterogeneity increase with disease
and HLA-DR15 status, which is particularly clear from the ‘single-
well’ view of PBMCs (Fig. 2B). Here, each column represents a
single donor with all seeded wells. Each well is represented by a
white dot. Donors were sorted by the well with the highest counts
per minute and according to disease and HLA status.
Supplementary Table 1 summarizes the results of Fig. 2A and B.
Characterization of autologous
proliferating cultures
In order to characterize which cell population in the peripheral
blood mononuclear cells is responsible for autologous proliferation
we determined the percentage of CD4 + , CD8 + and memory
CD4 + T cells before and after 7 days of culture. As expected
autologous proliferation was primarily mediated by CD4 + T
cells, since their percentages were high at the time of starting
the assay and increased further until Day 7 (Fig. 3A), whereas
the initially low numbers of CD8 + T cells dropped (Fig. 3A) indi-
cating that under uninhibited culture conditions CD8 + T cells did
not proliferate to a significant extent. Further, we did not observe
major changes regarding the naı¨ve/memory CD4 + T cell popula-
tion composition (Fig. 3A). However, the slight but consistent de-
crease of CD4 + CD45RO + T cells indicates that autologous
proliferation is mediated to a larger extent by naı¨ve cells, i.e.
CD4 + CD45RO , then by memory T cells.
Next we wanted to address the potential contribution of the
level of baseline HLA-DR expression or its upregulation during
the culture period. As shown in Fig. 3A, DR expression on B
cells increased significantly, supporting a putative role of HLA-
DR in the above phenomena. We then asked whether a higher
baseline HLA-DR/DR15 expression on antigen presenting cells is a
consequence of for example a proinflammatory environment in
multiple sclerosis and then causes increased homeostatic prolifer-
ation. Towards this aim we examined the HLA-class II expression
(DR, DP and DQ) on plasmacytoid dendritic cells, monocytes and
B cells in healthy donors and patients with multiple sclerosis homo-
zygote or heterozygote for DR15 as indicated by Cella et al.
(1997). HLA-class II expression did not differ significantly between
donors with the exception of lower levels of HLA-DR expression
on monocytes of patients with multiple sclerosis (Fig. 3B). Also,
there was no DR-related gene dosage effect in DR15 homozygous
versus heterozygous patients with multiple sclerosis or healthy
donors. Finally, blocking antibodies against HLA-class II alone
Figure 1 Comparison of autologous proliferation of peripheral mononuclear cells. Significant differences in proliferation strength
(A) [mean counts per minute (cpm)  SEM] and heterogeneity (B) (SD  SEM) are observed between multiple sclerosis (MS) and healthy
donors (HD) at Day 7 (*P50.05). (A) Right bar graph depicting the phytohaemagglutinin (PHA) positive control. (C) Example of one
multiple sclerosis donor showing all unstimulated wells over a 7-day proliferation assay with adjacent scheme explaining measures of
proliferation strength and heterogeneity.
Role of HLA-DR15 in multiple sclerosis Brain 2013: 136; 1783–1798 | 1787
(Fig. 3C) and against both HLA-class I and class II (Fig. 3C)
reduced the autologous proliferation in a dose-dependent
manner at Days 3 and 7 (Fig. 3C). Together these data indicate
that interactions between CD4 + T cells and their T cell receptor
with self HLA-class II molecules are involved in autologous prolif-
eration, that B cells may play a role in this phenomenon in vitro
and that different levels of HLA-class II expression at baseline are
unlikely to be involved.
Elution of HLA-DR-derived
self-peptides from the DR alleles
expressed in the multiple
sclerosis-associated DR15 haplotype
The above observations point at an involvement of the two DR15
alleles, DRB1*15:01 (DR2b) or DRB5*01:01 (DR2a) and the self-
peptides they display in increased autologous T cell proliferation in
DR15 + patients with multiple sclerosis. Multiple factors could con-
tribute to this observation including a genetically determined lower
activation threshold of T cells in multiple sclerosis and a T cell
receptor repertoire that is shaped in DR15 + individuals by central
tolerance mechanisms, which has higher affinity for DR15/self-
peptide complexes. With respect to the latter, structural features
of the DR molecules, i.e. their contact surfaces with the T cell
receptor of CD4 + T cells, or the spectrum of bound self-peptides
or both could play a role. To address the latter aspect we next
examined the nature of self-peptides and their potential role in
increased autologous proliferation by characterizing self-peptides
that are bound to DR2a and DR2b by peptide elution
and sequencing by mass spectrometry (schematically shown in
Fig. 4A). In a previous study, we employed Epstein-Barr virus-
transformed B cell lines that co-expressed all alleles of the DR15
haplotype using a monoclonal antibody against monomorphic
determinants of DR alleles (Vogt et al., 1994). To focus on
DR2a and DR2b directly, we here used bare lymphocyte syndrome
patient-derived B cell lines that had been transfected with either
DR2a or DR2b and did not express any other HLA-class II mol-
ecule. Furthermore, for precipitation of DR2a and DR2b molecules
we used allele-specific monoclonal antibodies against DR2a or
DR2b, respectively. Owing to the lower precipitation efficiency
of the latter IgM antibodies, a second sequential immunoprecipita-
tion was performed with the L243 antibody. Since bare lympho-
cyte syndrome transfectants only express one class II allele, the
Figure 2 Influence of HLA-DR15 haplotype on autologous proliferation. (A) Proliferation strength is shown for multiple sclerosis (MS) and
healthy donors (HD) together (left graph) or subdivided into HLA-DR15 haplotype-positive and -negative patients and healthy donors
(right graph) (mean counts per minute  SEM). (B) Proliferation heterogeneity is shown for multiple sclerosis and healthy donors together
(left graph) or subdivided into HLA-DR15 haplotype-positive and -negative patients and healthy donors (standard deviation  SEM).
(B) Each column represents one donor with dots displaying every single unstimulated well (thymidine incorporation at Day 7; *P50.05,
average wells per donor = 22).
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peptide elution presumably underestimates the relative presence of
HLA-class II-derived peptides by limiting the number of available
class II molecules. We eluted and identified a total of 154 peptides
from DR2a and DR2b molecules (Fig. 4A and Supplementary Table
2), and 7.14% (without considering multiple protein hits) of these
peptides were derived from DR (DRA1*01:01) or the b chains of
DR2b (DRB1*15:01) or DR2a (DRB5*01:01). Hence, HLA-class II
molecule-derived self-peptides form a substantial fraction of the
spectrum of self-peptides that are bound to the multiple sclerosis-
associated DR15 alleles. Biological pathway gene ontology anno-
tation of the eluted peptides demonstrated that many of them are
assigned to the antigen presentation pathway (Supplementary
Figure 3 T cell subpopulations and HLA-DR expression. (A) FACS analysis of CD4 + , CD4 + CD45RO + and CD8 + surface expression on
CD3 + T cells as well as the HLA-DR expression changes on B cells during 7 days of unstimulated PBMCs proliferation of five healthy
donors (HD). (B) HLA-class II expression (median fluorescent intensity; Med FI) on different antigen presenting cells of HLA-DR15-positive
and -negative patients with multiple sclerosis (MS) and healthy donors: CD303 + plasmacytoid dendritic cells, CD14 + monocytes and
CD19 + B cells. (C) Blocking of autologous proliferation using anti-HLA class I- and -DR-specific antibodies. Inhibition of proliferation was
measured on Days 3 and 7 and is shown as per cent of uninhibited proliferation.
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Figure 4 HLA-DR2a and –DR2b-specific peptide elution and characterization, and HLA-DR15 haplotype-derived self-peptide library.
(A) Schematic drawing of peptide elution from bare lymphocyte syndrome cells expressing only DRB1*15:01 (DR2b) or DRB5*01:01
(DR2a), respectively. (B) Pictogram illustrating the composition of the HLA-DR15 haplotype-derived library of self-peptides (15-mers).
(C) Exon 2 sequences of DRB1*15:01 and DRB5*01:01. Origin of allele-specific DRb chain-derived peptides and peptides with shared
sequences are depicted with single- and red and orange colours.
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Table 3). Herewith we confirm and broaden our earlier results that
HLA-class II-derived self-peptides make up a considerable portion




is related to expression of the
haplotype itself
The above data indicate that HLA-derived self-peptides probably
participate in autologous proliferation and also in T cell activation/
stimulation beyond autologous turnover. To address this point we
generated a HLA-DR15 haplotype-derived self-peptide library con-
sisting of 15-mer peptides with five amino acid overlaps spanning
the whole HLA-DR15 haplotype protein sequence (Fig. 4B). The
resulting 122 peptides were derived from five proteins, i.e. the
polymorphic chains HLA-DRB1*15:01 (DR2b), HLA-DRB5*01:01
(DR2a), the conserved HLA-DRA*01:01, and the HLA-DQw6
molecule consisting of HLA-DQA1*01:02 and HLA-DQB1*06:02
(Fig. 4B and Supplementary Table 4). HLA-DRb chains share most
of their sequences and are only polymorphic in certain areas, and
therefore peptides derived from shared sequences were only
synthesized once (Fig. 4B and C).
Since the relative genetic risk conferred by the multiple sclerosis-
associated HLA-DR15 haplotype correlates not only with DR15
carrier status, but also with its dose, i.e. homo- versus heterozy-
gosity (Barcellos et al., 2003; Cournu-Rebeix et al., 2008) we used
the entire HLA-derived peptide library, i.e. 24 pools of five pep-
tides each, to stimulate PBMCs from patients with multiple scler-
osis/healthy donors (20 donors each) that were stratified
according to DR15 homo- and heterozygosity (Fig. 5A). Since
large genetic studies had indicated that there are also HLA-DR
alleles that are ‘protective’ for multiple sclerosis, e.g. the HLA-
DR14 haplotype (Ramagopalan et al., 2007), we included a
HLA-DR15/’protective’ cohort (HLA-DRB1*14, HLA-DRB1*11),
which should have the lowest risk for multiple sclerosis develop-
ment regarding HLA background. We did not find these ‘protect-
ive’ DR alleles among our patients with multiple sclerosis, and
therefore only tested healthy donors. Figure 5A depicts the per
cent of wells with an stimulatory indices 4 2.0 of all peptide pools
tested for the different donors. Although the differences did not
reach statistical significance (Fig. 5A), there is a clear trend that
the reactivity increases from protective DR allele carriers to DR15
heterozygous to homozygous DR15 carriers. Owing to the higher
background/autologous proliferation in patients with multiple
sclerosis (see above), which affects the calculation of the stimula-
tory index, effects are more pronounced in healthy donors. In
addition, we tried to capture not only proliferating cells according
to standard criteria, i.e. surpassing background proliferation by at
least a factor of two (stimulatory indices42), but also those
showing a ‘low-grade’ proliferation (defined as stimulatory indi-
ces41.4). Since we added here nominal peptide in distinction
to the above unstimulated condition, which we referred to as
autologous proliferation, we will from now on refer to the pep-
tide-induced ‘low-grade’ proliferation as ‘tonic’ stimulation. As
shown in Fig. 5A, the tonic stimulation also increases in relation
to DR15 haplotype and homozygosity.
Potential role of HLA-DR15
haplotype-derived self-peptides
in autologous T cell proliferation
Next, we assessed the stimulatory or inhibitory potential of the
HLA-derived self-peptides (Fig. 5B). Selected individual HLA-
DR15-derived self-peptides were tested after analysing the prolif-
eration of 35 donors (20 patients with multiple sclerosis, 15
healthy donors) to the 24 pools of self-peptides (Supplementary
Fig. 2). Additionally, because they are most likely to be presented
in vivo, we also tested two peptides that had been eluted. Peptide
8 (SDVGEFRAVTELGRP) and its DR2a homologue have been
eluted twice, once by Vogt et al. (1994) and again from DR2a
in the present study. Peptide 54 (EEFGRFASFEAQGAL) was eluted
from HLA-DR2b. Like peptides 14, 15, 20 and 45, both elicited
strong T cell proliferation (Fig. 5B). These experiments demon-
strate that distinct DR15 haplotype-derived self-peptides are
stimulatory to bulk PBMCs, whereas other peptides seem to inhibit
activation or proliferation (stimulatory indices4 2.0). As described
in Fig. 5A, we used the thresholds of stimulatory indices42.0
and41.4, respectively, to discriminate between activation and
tonic proliferation. When looking at one specific peptide as an
example, peptide 45, 12.5% of all wells proliferated with stimu-
latory indices42.0 (Fig. 5C) and 66% with stimulatory indi-
ces4 1.4 (not shown) indicating that a large number of wells
responds with a tonic proliferation pattern, and a fraction of
cells is fully activated. Interestingly, peptide 45 showed a
marked T cell response despite originating from the inhibitory
pool number 9 supporting the consideration that inhibitory and
stimulatory peptides within each pool interact, consequently
explaining the low overall proliferative response to the peptides
pools (Supplementary Fig. 2).
We further asked if the stimulatory HLA-DR15-derived self-
peptides could, if pooled together, evoke a stable T cell prolifer-
ation and if so, which concentrations are sufficient to induce
proliferation. For this purpose different doses between 0.1 and
20 mM of a pool of five strongly stimulatory peptides were used.
Peptide 54 had been eluted, peptides 8 and 20 were analogues
of eluted peptides, and peptides 14 and 45 demonstrated the
strongest tonic proliferation stimulus in the above proliferative
assays with individual peptides. As shown in Fig. 5C, the pool
of stimulatory peptides led to full stimulation and also tonic pro-
liferation over a wide range of concentrations with a peak at
1.0 mM (Fig. 5C).
Next, we used the above five stimulatory peptides and exam-
ined the HLA-class II restriction using purified CD4 + T cells and
bare lymphocyte syndrome transfectants expressing either DR2b,
DR2a or DQw6. Most of the peptides elicited their stimulatory
effect when presented by HLA-DR2a (Fig. 5D). Interestingly,
when they were added to antigen presenting cells expressing
HLA-DQw6, most peptides showed inhibitory rather than stimu-
latory effects.
Role of HLA-DR15 in multiple sclerosis Brain 2013: 136; 1783–1798 | 1791
Figure 5 Proliferation of peripheral blood mononuclear cells upon stimulation with HLA-DR15 haplotype-derived self-peptides.
(A) Per cent positive wells tested against 24 pools of HLA-DR15-derived self-peptides. Patients with multiple sclerosis (MS) (MS risk
n = 10, MS hetero n = 10) and healthy donors (HD) (HD risk n = 7, HD hetero n = 8, HD protective n = 5) were stratified according to
HLA-DR15 status as depicted by the schematic on the right. Risk indicates homozygosity for HLA-DR*15, hetero indicates HLA-DR*15/
*X, and donors with protective alleles carry HLA-DR*15/*14 or -*11 haplotypes. Per cent positive wells with stimulatory indices4 2.0
(left graph) and stimulatory indices41.4 (right graph). (B) Proliferation of PBMCs to individual HLA-DR15-derived self-peptides (% of
wells4 stimulatory indices 2.0, n = 6) grouped by stimulatory, inhibitory and eluted peptides. (C) The most stimulatory peptides from B
(peptide 8, 14, 20, 45, 54) were pooled and tested in a dose titration experiment. Per cent wells with stimulatory indices42 and
stimulatory indices41.4 are shown (n = 6). (D) Proliferation of isolated bulk CD4 + T cells in response to five HLA-derived peptides
presented by antigen presenting cells (bare lymphocyte syndrome transfectants) expressing only DR2a, DR2b, or DQw6 respectively
[mean stimulatory index (SI) with SEM using five donors, six wells each].
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Characterization of polymorphic
HLA-DRb-derived peptides
Finally, we compared corresponding peptides derived from the
polymorphic regions of the two DRb chains (Fig. 6; see also
Fig. 4C). We found significant differences in 5 of 10 pairs
(Fig. 6). In four of the five pairs DR2b-derived peptides (Fig. 6,
light grey) were more stimulatory, whereas we found the reverse,
i.e. that the DR2a-derived peptide was more stimulatory, only for
peptide 44 versus peptide 22. Peptide 4 (DTRPRFLWQPKRECH,
DR2b-derived) gave the strongest proliferative response of all
polymorphic peptides. Tables 1 and 2 summarize all allele-specific
DRb chain-derived peptides, which we compared in Figure 6. In
order to understand better, if these peptides bind to either of
the two DR15 molecules, DR2a and DR2b, or to DQw6, we
performed well-established in silico peptide binding predictions.
The predicted binding affinities (% consensus rank; low values
indicate better binding; highest affinity highlighted in green) are
summarized in Table 1, and we further mention if the respective
peptide was eluted from DR15 molecules in this or our prior study
(Vogt et al., 1994). Table 2 additionally analyzes peptides that
have been eluted or shown to be stimulatory in our experiments.
Both tables depict the peptide origin and the probability of being
presented by an HLA-class II molecule of the DR15 haplotype.
Discussion
Despite substantial progress in immunology we still know remark-
ably little about how certain HLA-class II alleles contribute to auto-
immune diseases (Gronski et al., 2004; McFarland and Martin,
2007). HLA-DR15 as major risk factor for multiple sclerosis is
one of the most striking examples for this notion. The mechanisms
as to how HLA-DR15 shapes and maintains an autoreactive T cell
repertoire that leads to CNS autoimmunity are still elusive despite
longstanding efforts by a number of groups including our own,
which focused primarily on studying the antigen specificity, func-
tion and HLA restriction of autoreactive T cell clones. In the pre-
sent study we explored a hypothesis that had been discussed
earlier in the context of autoimmune liver disease (Burroughs
et al., 1992) and oligoarticular juvenile idiopathic arthritis (Massa
et al., 2002) but not for multiple sclerosis so far. These studies
postulate that self-peptides derived from and presented by abnor-
mally expressed HLA-class II molecules potentially mimic micro-
bial/viral peptides and may serve as target for the autoimmune
T cell responses. Based on the consideration that interactions be-
tween HLA-class II molecules and the T cell receptors of CD4 + T
cells are, besides IL-7, the most important factor to keep periph-
eral T cells alive, we examined the functional involvement of the
HLA-DR15 haplotype in shaping and/or maintaining the peripheral
T cell repertoire in multiple sclerosis through autologous prolifer-
ation. It has to be clarified, however, that we cannot assess by our
simplified in vitro system the complex in vivo interactions that
lead to T cell repertoire maintenance. Different from the steady-
state in vivo homeostatic proliferation, i.e. in the absence of lym-
phopenia, which involves HLA/MHC/self-peptide complexes and/
or IL-7 depending on the cell type (Baccala and Theofilopoulos,
2005; Cox et al., 2005), our assay system most likely depicts a
combination of autologous activation and subsequent proliferation
in the absence of any stimulus. As stated above, this setting is
different from the well-examined autologous mixed lymphocyte
reaction, where antigens that are generated by apoptosis of the
Figure 6 Reactivity to HLA-DRb chain-derived, allele-specific self-peptides. Comparison of 20 peptides derived from the polymorphic
HLA-DRb chains of DRB1*15:01 and DRB5*01:01 (five donors, eight wells each; *P-value50.05). Scheme depicting origin of allele-
specific peptides and shared peptide regions of the DRb-derived sequence.
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Origin of peptide Position in
sequence
Sequence to DR2b to DR2a to DQw6 Remarks
binding affinity of peptides
% consensus rank
3 DRB1*15:01 (DR2b) ()9 to 6 VLSSP LALSG DTRPR 51,16 20,79 24,93
29 DRB5*01:01 (DR2a) VLSSP LALAG DTRPR 54,26 21,62 11,64
4* DRB1*15:01 (DR2b) 2 to 16 DTRPR FLWQP KRECH 44,19 8,23 85,72 Polymorphic region incl.
mutation described by
Zipp et al. (2000)
30* DRB5*01:01 (DR2a) DTRPR FLQQD KYECH 65,06 19,57 85,72
5* DRB1*15:01 (DR2b) 12 to 26 KRECH FFNGT ERVRF 29,81 5,79 84,80
31* DRB5*01:01 (DR2a) KYECH FFNGT ERVRF 30,83 5,79 86,38
6 DRB1*15:01 (DR2b) 22 to 26 ERVRF LDRYF YNQEE 2,01 14,87 94,16
32 DRB5*01:01 (DR2a) ERVRF LHRDI YNQEE 26,40 27,88 80,89
8 DRB1*15:01 (DR2b) 42 to 56 SDVGE FRAVT ELGRP 43,62 0,38 37,84 Eluted by Vogt et al. (1994)
34 DRB5*01:01 (DR2a) SDVGE YRAVT ELGRP 46,97 0,49 39,70 Eluted from DR2a
10 DRB1*15:01 (DR2b) 62 to 76 NSQKD ILEQA RAAVD 22,57 27,55 21,18
35 DRB5*01:01 (DR2a) NSQKD FLEDR RAAVD 41,36 31,98 81,95
14* DRB1*15:01 (DR2b) 102 to 116 YPSKT QPLQH HNLLV 36,20 46,73 78,73
39* DRB5*01:01 (DR2a) YPART QTLQH HNLLV 34,29 35 56,98
16* DRB1*15:01 (DR2b) 112 to 126 FYPGS IEVRW FLNGQ 49,58 39,37 49,00
41* DRB5*01:01 (DR2a) FYPGS IEVRW FRNSQ 51,21 29,98 55,42
22* DRB1*15:01 (DR2b) 182 to 196 SPLTV EWRAR SESAQ 51,07 25,72 69,38
44* DRB5*01:01 (DR2a) SPLTV EWRAQ SESAQ 62,42 23,55 62,53
25 DRB1*15:01 (DR2b) 212 to 226 FLGAG LFIYF RNQKG 0,51 1,69 41,68
45 DRB5*01:01 (DR2a) FLGAG LFIYF KNQKG 0,89 1,69 49,87
Polymorphic amino acids are marked in red, the highest predicted binding affinity (consensus rank5 20%) to one of the alleles with green shading, and the peptide giving
stronger responses in proliferation testing is indicated by grey shading.








Sequence to DR2b to DR2a to DQw6 Remarks
binding affinity of peptides
% consensus rank
19 shared DRb 152 to 166 DWTFQ TLVML ETVPR 12,25 1,43 8,32 Eluted from DR2a
20 shared DRb 162 to 176 ETVPR SGEVY TCQVE 81,63 64,18 62,29 Euted from DR2a
54 DRA*01:01 56 to 70 EEFGR FASFE AQGAL 2,64 5,42 15,95 Eluted by Vogt et al. (1994).,
eluted from DR2b
104 DQB1*06:02 39 to 53 RFDSD VGVYR AVTPQ 28,86 20,38 32,67 Eluted by Vogt et al. (1994),
analogue eluted from DR2a
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irradiated stimulator cells are recognized by autologous T cells
(Amel Kashipaz et al., 2002), which probably also explains the
divergent results between autologous mixed lymphocyte reaction
in multiple sclerosis, i.e. decreased proliferation (Hafler et al.,
1985), and our observation of increased autologous proliferation.
With advanced age thymic output decreases, and hence com-
pensatory peripheral homeostatic proliferation becomes more im-
portant for maintaining a functional T cell repertoire (Naylor et al.,
2005). Previous studies have described earlier thymic involution as
well as reduced generation of CD4 + recent thymic emigrants
in multiple sclerosis (Duszczyszyn et al., 2010). Here, we show
elevated autologous T cell proliferation in patients with multiple
sclerosis compared with healthy donors in our experimental
in vitro system. The autologous proliferation is more heteroge-
neous in that a substantial fraction of cells shows signs of full
activation in patients with multiple sclerosis, and it is related to
the multiple sclerosis-associated HLA-DR15 haplotype. Based on
the importance of HLA-class II molecules, presented self-peptides
and the T cell receptor avidity (Sprent and Surh, 2011) for this
process, we assume that the HLA-DR15 haplotype is involved in
altered homeostatic T cell proliferation in multiple sclerosis.
Because the patients with multiple sclerosis of this study were
not lymphopenic, i.e. did not have a relative depletion of the
lymphocyte niche, it appears that lymphocytes are not numerically
reduced, but rather that their repertoire is more narrow with re-
spect to different specifities, but enriched for T cells with higher
affinity for self-peptide. Such a repertoire is then expected to be
activated easier in an autologous setting, which is simulated by our
in vitro system.
Although immune mechanisms exist that sustain a T cell reper-
toire of great diversity (Min et al., 2004) previous studies have
reported that the peripheral maintenance of naı¨ve T cells is not
random (Rudd et al., 2011). Under homeostatic conditions T cell
receptor affinity/avidity appears to regulate T cell survival (Kieper
et al., 2004). In line with these concepts, we have previously
shown that the presentation of self-peptides by mature dendritic
cells can lead to a state of preactivation of T cells (Kondo et al.,
2001). Together, these studies emphasize that homeostatic/
autologous proliferation supports mechanisms of selection and
preferential activation of certain parts of the T cell repertoire.
Therefore, the heterogeneous autologous proliferation with some
cells showing a tonic response and others signs of full activation
could indicate a process of selection through predominant prolif-
eration of certain sets of T cells expressing T cell receptors with
higher avidities for self-MHC/self-peptide complexes.
During T cell activation the T cell receptor contacts both anti-
genic peptide and HLA backbone. The two alpha-helices of the
HLA backbone represent over 60% of the T cell receptor:MHC/
peptide interaction surface (Sundberg et al., 2007). When dissect-
ing the trimolecular complex (T cell receptor:MHC/peptide), the
following considerations are important. First, the higher the con-
tribution of the HLA backbone to overall avidity the higher the
number of peptides that can be recognized by the T cell receptor.
Second, because T cell activation (or prevention of death) is
related to T cell receptor affinity, selection is a consequence of
homeostatic T cell proliferation. Third, the composition of self-pep-
tides that are presented by a given HLA molecule is constrained by
structural aspects of its binding pockets. Fourth, the presenting
HLA molecule itself, which passes through the main processing
compartments, is an important source of peptides that are
displayed in its own binding pockets (Dengjel et al., 2005).
Therefore, HLA haplotypes present a haplotype-specific diverse
set of self-peptides, which probably participates in shaping the
peripheral T cell repertoire. As our in vitro studies show that the
heterogeneity of proliferation was enhanced by the HLA-DR15
haplotype, we hypothesize that either the structural configuration
of the HLA backbone, the self-peptides presented by the HLA-
DR15 haplotype, or a combination of both are at least in part
responsible for the observed proliferation patterns.
Most of the time surface HLA-class II molecules are loaded with
self-peptides (Schild et al., 1990). To analyse the potential role of
self-peptides derived from the multiple sclerosis-associated HLA-
DR haplotype and thus address some of the above possibilities, we
eluted peptides presented by the HLA-DR15 haplotype. Consistent
with previous work including ours (Vogt et al., 1994; Dengjel
et al., 2005) we identified self-peptides from various sources
and mostly from processing- and antigen presentation-related
molecules. Among the latter a substantial fraction was derived
from molecules of the HLA-DR15 haplotype itself. Our data indi-
cate that HLA-derived self-peptides play an important role in the
observed HLA haplotype-specific differences in autologous prolif-
eration and that they can promote T cell proliferation. By using
systematically generated sets of peptides spanning all DR- and DQ
- and b chains, we demonstrate that relatively high frequencies
of peripheral T cells recognize certain HLA-derived self-peptides.
Although T cell proliferation is often tonic, full activation is not a
rare event even without any antigenic stimulus in PBMCs from
patients with multiple sclerosis. These data indicate that HLA-
DR15-derived self-peptides are able to provide a low-level stimu-
lus or fully activate parts of the peripheral T cell repertoire.
Furthermore, the observed HLA-derived peptide reactivity corre-
lated with the genetic risk conferred by the HLA-DR haplotype. In
individuals, who are haploidentical with respect to HLA-class II
type, the combined effects of stimulatory and inhibitory self-pep-
tides derived from multiple sclerosis risk-conferring and/or risk-
lowering HLA alleles probably participates in setting the activation
thresholds of T cells.
Positively selecting self-peptides in the context of CD4 + T cells
have recently been described in murine models (Lo et al., 2009),
and the most important conclusions from these studies were the
high specificity in the recognition of positively selecting ligands
and that the same self-peptides can support peripheral homeo-
static proliferation or serve as coagonists in the recognition of
nominal ligand (Krogsgaard et al., 2007; Wucherpfennig and
Gagnon, 2009). Because the number of self-peptides that are
involved in thymic selection processes is considered to be small,
and many of these are presented both on thymic- and peripheral
antigen presenting cells, they are probably relevant in both con-
texts, i.e. during central selection and peripheral homeostasis.
Although thymic T cell repertoire selection appears to depend pri-
marily on T cell receptor:MHC/peptide affinity, the peripheral
maintenance and selection is determined by T cell receptor
cross-reactivity (Hao et al., 2006). Regarding the latter, the
T cell receptor cannot distinguish between self- and non-self
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peptides (Ashton-Rickardt et al., 1994; Krogsgaard et al., 2007),
and therefore self-peptides presumably are a major factor in shap-
ing and maintaining the composition of the peripheral T cell rep-
ertoire. Since HLA molecules bind different sets of peptides based
on the structural requirements of their binding pockets (Falk et al.,
1994), different self-peptide repertoires will be presented accord-
ing to haplotype. These factors together with the structural char-
acteristics of the exposed surface of HLA molecules most likely
lead to HLA haplotype-specific shaping of the T cell receptor
repertoire.
Besides these structure-related possibilities our data point at yet
another one, which involves peptides derived from the non-poly-
morphic or polymorphic stretches of HLA molecules as antigens
themselves. Interestingly, an earlier study on the role of poly-
morphic regions of different DRB1* alleles including DRB1*15:01
observed significant multiple sclerosis-association of the amino
acids proline at position 11, arginine at position 13, and alanine
at position 71 of HLA-DRB1*15:01 (Zipp et al., 2000). This study
did not examine the DRB5* allele nor the abovementioned struc-
tural contributions or role of a polymorphic DR-derived peptide as
antigen. In our present study, HLA-derived peptide number 4 con-
tains both proline at position 11 and arginine at position 13, and
therefore this peptide could contribute to increased autologous
proliferation by shaping the binding pocket of DR2b, or conversely
it could be an antigen itself. Peptide 4 was the most stimulatory of
the polymorphic areas (see Fig. 6B), whereas the homologous
peptide 30 derived from the same area of DRB5*01:01 was not
stimulatory.
If one attempts to link these findings to multiple sclerosis, it is
currently believed that autoreactive T cell responses in multiple
sclerosis are directed against myelin proteins including myelin
basic protein (MBP) (Sospedra and Martin, 2005). Early studies
by others and us have found MBP-specific T cells in patients
with multiple sclerosis, but also in healthy controls (Martin
et al., 1990; Ota et al., 1990; Pette et al., 1990). Despite
higher precursor frequencies in patients with multiple sclerosis in
some studies this observation at first seemed to argue against a
role of these cells in multiple sclerosis, but later studies not only
described higher frequencies, but also other potentially relevant
characteristics such as higher functional T cell receptor avidity
against several myelin peptides derived from MBP, myelin oligo-
dendrocyte glycoprotein (MOG) and proteolipid protein (PLP)
(Bielekova et al., 2004), populations that are independent of
costimulation (Markovic-Plese et al., 2001), signs of activation
(Bielekova et al., 1999) and enrichment in the naı¨ve CD4 +
T cell compartment (Muraro et al., 2000). An interesting question
is if the increased autologous turnover that we describe here, also
leads to conversion to memory phenotype in autoreactive T cells,
which would explain the increased numbers of MBP-specific
memory cells in patients with multiple sclerosis (Burns et al.,
1999). In line with this speculation, investigations of the CD8 +
T cell compartment show that T cell numbers and diversity
decrease with age, surviving T cells undergo faster rates of
homeostatic proliferation, are selected for high T cell receptor
avidities, and preferably acquire ‘memory-like’ phenotype (Rudd
et al., 2011). The relatively early thymic involution that was
described in multiple sclerosis (Duszczyszyn et al., 2010) could
lead to an increased demand for compensatory peripheral homeo-
stasis in the CD4 + compartment as observed in the autologous
proliferation setting. A combination of the presented HLA haplo-
type-specific self-peptides and structural features of the HLA-
DR15 haplotype may lead to alterations in the overall strength
and quality of proliferation with the consequence of selecting an
‘autoimmune-prone’ T cell repertoire.
Another important aspect is the question if only DRB1*15:01 or
also DRB5*01:01 determines multiple sclerosis risk. A number of
studies indicate the former, i.e. that risk is only conferred by
DRB1*15:01 (Caillier et al., 2008). We favour that both alleles
contribute jointly to multiple sclerosis risk based on the similarities
of the peptide binding motifs (Vogt et al., 1994; Wucherpfennig
et al., 1994), which lead to presentation of similar peptides includ-
ing the immunodominant MBP83–99 peptide, which can be pre-
sented equally well by both alleles (Martin et al., 1991; Valli
et al., 1993; Wucherpfennig et al., 1994). Also, humanized
transgenic mice expressing a multiple sclerosis patient-derived
MBP83–99-specific T cell receptor and DR2a (DRB5*01:01) develop
spontaneous experimental autoimmune encephalomyelitis
(Quandt et al., 2012) as do transgenic mice expressing a
MBP84–102-specific T cell receptor and DR2b (DRB1*15:01)
(Madsen et al., 1999). Furthermore, myelin-specific- and virus-
specific T cell clones, which recognize the same and different pep-
tides in the context of both DR2a and DR2b, have been described
(Lang et al., 2002; Sospedra et al., 2005), and that their cross-
restriction leads to higher antigen avidity (Sospedra et al., 2006;
Yousef et al., 2012). Here, we observe that the majority of HLA-
derived polymorphic peptides that stimulate T cell proliferation are
derived from DR2b (e.g. peptides 4 and 8), however, when exam-
ining their peptide binding to the two DR molecules, both show
stronger affinity, are restricted by and have been eluted from
DR2a (Fig. 6). We observed the reverse with peptide 45.
Finally, we found non-polymorphic peptides, i.e. peptide 54
derived from DRA1*, which is predicted to bind better to DR2b
and which we had also previously eluted from DR2b (Fig. 6C),
although the bulk CD4 + T cells recognize the peptide when pre-
sented by DR2a (Fig. 6A). These data do not answer definitively
the above question, which of the two alleles is more relevant for
shaping an autoimmune-prone T cell repertoire in DR15 + patients
with multiple sclerosis, but they support the notion that both are
involved.
Taken together, our observations are in line with previous re-
ports describing early thymic involution and repertoire narrowing
in patients with multiple sclerosis. The subsequent demand for an
increased peripheral maintenance and the accompanying effects
on T cell receptor repertoire selection are reflected not only in
the enhanced-, but also in a more heterogeneous proliferation
pattern. Further, we demonstrate that the HLA-DR15 haplotype-
derived self-peptides and/or structural features of the two
HLA-DR molecules of the DR15 haplotype are likely involved in
increased autologous proliferation. It remains to be shown if T cells
that are expanded by autologous proliferation have the propensity
to cross-react with myelin- or CNS autoantigens as indicated by
(Cai and Hafler, 2007), can be activated by peptides from foreign
agents and if the autologous proliferation leads to preferential
differentiation into proinflammatory T cells. There are probably
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additional factors that contribute to the proliferation patterns
including cytokine receptors, cytokines, costimulatory molecules
and their ligands, CD4-HLA-class II co-receptor interactions, and
integrin/adhesion molecules, which may all be involved in regulat-
ing the threshold for T cell activation, expansion or functional
differentiation. Interestingly, single nucleotide polymorphisms of
a number of these (IL7RA, IL2RA, IL7, CD58, CBLB, CD40,
IL12B, IL22RA2, and others) have been found to be involved in
multiple sclerosis risk (Sawcer et al., 2011). Based on our obser-
vations and the genetic data, we propose the following model.
The two DR alleles in the DR15 haplotype and as yet unknown
self-peptides select by central tolerance mechanisms a T cell re-
ceptor repertoire that has the inherent propensity to recognize
CNS autoantigens and lead to a CNS-specific autoimmune T cell
response. Positively selected T cells are maintained and/or ex-
panded by peripheral homeostatic proliferation, which again in-
volves the two DR15 alleles and according to our data among
the spectrum of self-peptides also those derived from the DR15
haplotype themselves. Both a genetically predetermined lower ac-
tivation threshold and certain environmental triggers then finally
lead to full activation and expansion of CNS-autoreactive T cells,
their proinflammatory differentiation and eventually the develop-
ment of multiple sclerosis.
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